Analyst Site Visit
December 12 2003 - 2:00AM
UK Regulatory
RNS Number:1754T
Bespak PLC
12 December 2003
For immediate release 12 December 2003
Bespak plc
Analyst Site Visit
Bespak (LSE: BPK), the drug delivery company, announces that it is holding a
site visit today for analysts at its newly extended King's Lynn facility in
Norfolk.
The visit will involve a tour of the site, as well as presentations from senior
management on key areas of the business including Device & Manufacturing
Services, Respiratory Drug Delivery and Operations. The visit will provide
analysts with an update on the Company's growth strategy together with an
opportunity to gain an in-depth awareness and understanding of Bespak's
business.
No material new financial information will be disclosed today. The Group plans
to announce its Preliminary results on 20 January 2004.
For further information please call:
Bespak plc Tel: +44(0)1908 552600
Mark Throdahl, CEO
Buchanan Communications Tel: +44(0)20 7466 5000
Tim Thompson, Mark Court, Mary-Jane Johnson
Notes to editors
About Bespak plc
Bespak is in the forefront of developing new delivery systems for the
pharmaceutical industry. The company has a product range covering metered dose
inhalers, dry powder devices, actuators and compliance aids. The company also
develops and manufactures drug delivery devices for leading global
pharmaceutical companies such as the DiskusTM dry powder inhaler, the drug
delivery device used in GlaxoSmithKline's blockbuster asthma treatment Advair/
Seretide. The group has facilities in King's Lynn and Milton Keynes in the UK
and in Cary, North Carolina, in the USA. Bespak is a public company quoted on
the Official list of the London Stock Exchange (LSE: BPK). For more information
go to www.bespak.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGUGCAPUPWGQG